Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760625 | 0.88 | KEAP1 (0.57) | KEAP1EP300KAT2BKAT8KDM4E | |
| SCHEMBL4473631 | 0.80 | IDO1 (0.44) | KEAP1KDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL11509065 | 0.73 | KEAP1 (0.77) | KEAP1EP300KAT2BKAT8KDM4E | |
| SCHEMBL13483435 | 0.73 | EP300 (0.66) | KEAP1EP300KAT2BKAT8KDM4E | |
| SCHEMBL4313898 | 0.73 | BCAT2 (0.31) | KEAP1 | |
| SCHEMBL7407714 | 0.72 | RXFP1 (0.51) | KDM4EHPGDHSD17B10PARP14KMT2A | |
| SCHEMBL6066253 | 0.71 | IDO1 (0.49) | KDM4EHPGDHSD17B10GAAAR | |
| SCHEMBL11388125 | 0.71 | PABPC1 (0.46) | — | |
| SCHEMBL2124660 | 0.71 | KEAP1 (1.00) | KEAP1EP300KAT2BKAT8KDM4E | |
| SCHEMBL11289604 | 0.70 | GAA (0.53) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| WO-2005058292-A1 | NEW USE IN GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | KEAP1 687/4885EP300 3454/4885KAT2B 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.